A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

Clinical trial NCT05279859 · WITHDRAWN

Trial details

NCT number: NCT05279859
Sponsor: Erasca, Inc.
Status: WITHDRAWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia

Start date: 2022-03-15
Primary completion: 2025-03-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.